Revolution Medicines
RVMD
Performance
About Revolution Medicines
Revolution Medicines is a biopharmaceutical company focused on discovering, developing, and delivering targeted medicines for cancer, with a particular emphasis on Ras-driven or Ras-addicted cancers. The company pursues precision oncology through its pipeline and science programs, aiming to outsmart cancer by targeting oncogenic pathways. Headquartered in Redwood City, California, Revolution Medicines emphasizes translational science and novel targeted therapies to treat patients worldwide.
Recent News
ASCO26: 5 Data Snapshots Ahead of the Year’s Biggest Cancer Drug Meeting
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
FDA Grants Expanded Access to Revolution Medicines' Pancreatic Cancer Pill Daraxonrasib
STAT+: Finally Cracking KRAS as a Druggable Target
Revolution Medicines' Daraxonrasib Shows Survival Gain, Stock Up 39%
ASCO26: Revolution's 'Grand Slam' Data in Pancreatic Cancer
STAT+: Novartis CEO Joins Anthropic’s Board
Daraxonrasib (RMC-6236): The 2025 Molecule of the Year
Former Sen. Ben Sasse Shines the Spotlight on a Possible Breakthrough for Pancreatic Cancer
This Pill May Help Pancreatic Cancer Patients Live Longer
BBOT Shakes up Leadership as RAS Competitors Get More Visibility
Revolution Medicines Initiates P-III (RASolute 303) Trial of Daraxonrasib in Pancreatic Ductal Adenocarcinoma (PDAC)
Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100
Merck to Acquire Terns Pharmaceuticals for $6.7 B, Accelerating M&A Ahead of Keytruda Patent Expiry
FDA Expands Compassionate Use of Daraxonrasib for Metastatic Pancreatic Cancer
Report Says MSD Is in Talks to Buy Revolution Meds
Revolution Medicines Prices $2B Raise as XBI Reaches Heights Not Seen Since Pandemic
STAT+: The Race to Catch KRAS, Pancreatic Cancer’s ‘Greasy Ball,’ and Create the Most Promising Drug in Decades
Roche’s DAC Investment; Big Pharma’s Lavish CEO Bumps
Merck’s PD-1/VEGF Data Star in Stacked Lineup of AACR ‘26 Data Reveals
#AACR26 Preview: Revolution Medicines, the RAS Bonanza and China ADC Standouts
AACR 2026: Combo Therapies by Moderna, Marengo Show Promise in Skin, Breast Cancer
Former Senator Ben Sasse Joins Daraxonrasib Trial, Tumors Shrink 76% in Pancreatic Cancer
Revolution Rises 40% as Pancreatic Cancer Drug Doubles Survival
AACR 2026: Revolution’s Next Prospect, Merck’s Reveal and a Lung Cancer Battle
Abivax Climbs on Lilly Takeover Speculation
Founders Face Pressure From All Sides as Biotech Crawls Toward Recovery
Revolution Medicines' Daraxonrasib Cuts Pancreatic Cancer Death Risk by 60% – This Week in Biotech #96
F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer
FDA Approves the First PROTAC in History, a $1B siRNA Wave Hits Cardiometabolic Disease, and Cytokinetics Cracks Non-Obstructive HCM – This Week in Biotech #99
Revolution Medicines' Buyout Price Soars After Pancreatic Cancer Win
Experimental Pill Promises New Hope for Deadly Pancreatic Cancer
Revolution Medicines' Pancreatic Cancer Drug Doubles Survival Time in Phase 3
Behind the Headlines Episode 32: AI’s Power, NVIDIA & Lilly, Revolution Medicine
IShares Small‑Cap ETFs Clash: IJR’s Liquidity vs ISCB’s Low Cost
Speculation Builds About a Deal for Revolution Medicines
AI in Oncology Takes Off, Tackling HIV and Liver Disease, Pharma’s Recent Gains
STAT+: Can Erasca Be Biotech’s Next Big Thing? We’ll See
STAT+: Revolution Medicines Touts ‘Unprecedented’ Data for Pancreatic Cancer Pill
The Wild Card in the G12D Space
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline
Revolution Medicines Leads Latest Wave of Stock Offerings, Totaling $1.5B
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
Top 10 Most Popular Drug Hunter Case Studies of 2025
Alphabet Boosts Portfolio Value by $1.5 B, Adds CME Group as Top Holding
STAT+: Pharmalittle: We’re Reading About Sanofi and an FDA Voucher, FDA Rethinking a Rejection, and More
Can Revolution’s 'Miracle' Pancreatic Cancer Drug Be Topped? Immuneering, Actuate Say Yes
Bring on the Breakthroughs: ASCO Takes Translation to More Patients
STAT+: Revolution Medicines Starts Shipping Experimental Pancreatic Cancer Drug
Biotech Has Become a Good News Story. Let the Sun Shine